Drug design, development and therapy · 2026
Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults.
Клиническое исследование I фазыСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Panuganti Veerendra Kumar, Dundigalla Mamatha Reddy, Grandhi Venkata Ramalingayya, Khambhampaty Sridevi, Madala Pavan Kumar, Mohammad Javeed, Shaik Althaf, Shaik Mahaboob Basha, Kssvv Sanyasirao, Sangeetham Sai Kumar
Аннотация
PURPOSE: To compare the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of recombinant human serum albumin (rHSA) with plasma-derived human serum albumin (pdHSA) following intravenous administration to healthy adults.
PATIENTS AND METHODS: This Phase I study enrolled 62 healthy adults aged 18-45 years in two sequential parts. Part 1 (n=12) evaluated safety and tolerability of rHSA using a single ascending dose design (10 g, 20 g and 40 g) with 3 cohorts. Based on these outcomes, Part 2 (n=50) was conducted as a randomized (1:1), active-controlled, parallel-group study comparing rHSA with pdHSA (Flexbumin® 20%) administered at escalating doses (10 g, 20 g, and 40 g) with 3-week intervals. Primary PK endpoints were Cmax (1st dose) and AUC∞ (3rd dose). Secondary endpoints included PK parameters: Tmax (Time to peak concentration), t½ (Elimination half-life), Elimination rate constant (Kel) and CL (Clearance). PD markers: Colloid Osmotic Pressure (COP) and Hematocrit Ratio (HCT), Safety, Tolerability, and Immunogenicity.
RESULTS: In Part 1, rHSA was tolerated up to 40 g as single dose, and at cumulative dose of 70 g in part 2, with no dose-limiting toxicities. PK and PD profiles were comparable between test rHSA and pdHSA, with geometric mean ratios for Cmax and AUCt (baseline uncorrected) falling within the accepted 80-125% bioequivalence range. COP and HCT ratios were consistent across doses, indicating equivalent pharmacodynamic activity. No severe adverse events (SAEs) occurred during the study. All reported adverse events (AE) were mild-to-moderate in severity and resolved without sequelae. Low-titre IgG antibodies were detected in a few participants, without clinical relevance, with no IgE or anti-host cell protein (HCP) antibodies detected.
CONCLUSION: The test rHSA was well tolerated at cumulative doses of 70 g and demonstrated comparable PK, PD, safety and immunogenicity profiles to pdHSA, supporting its potential as a viable alternative.
PATIENTS AND METHODS: This Phase I study enrolled 62 healthy adults aged 18-45 years in two sequential parts. Part 1 (n=12) evaluated safety and tolerability of rHSA using a single ascending dose design (10 g, 20 g and 40 g) with 3 cohorts. Based on these outcomes, Part 2 (n=50) was conducted as a randomized (1:1), active-controlled, parallel-group study comparing rHSA with pdHSA (Flexbumin® 20%) administered at escalating doses (10 g, 20 g, and 40 g) with 3-week intervals. Primary PK endpoints were Cmax (1st dose) and AUC∞ (3rd dose). Secondary endpoints included PK parameters: Tmax (Time to peak concentration), t½ (Elimination half-life), Elimination rate constant (Kel) and CL (Clearance). PD markers: Colloid Osmotic Pressure (COP) and Hematocrit Ratio (HCT), Safety, Tolerability, and Immunogenicity.
RESULTS: In Part 1, rHSA was tolerated up to 40 g as single dose, and at cumulative dose of 70 g in part 2, with no dose-limiting toxicities. PK and PD profiles were comparable between test rHSA and pdHSA, with geometric mean ratios for Cmax and AUCt (baseline uncorrected) falling within the accepted 80-125% bioequivalence range. COP and HCT ratios were consistent across doses, indicating equivalent pharmacodynamic activity. No severe adverse events (SAEs) occurred during the study. All reported adverse events (AE) were mild-to-moderate in severity and resolved without sequelae. Low-titre IgG antibodies were detected in a few participants, without clinical relevance, with no IgE or anti-host cell protein (HCP) antibodies detected.
CONCLUSION: The test rHSA was well tolerated at cumulative doses of 70 g and demonstrated comparable PK, PD, safety and immunogenicity profiles to pdHSA, supporting its potential as a viable alternative.